Key result
Beta-blockers remain first-line for arrhythmias, with defibrillators recommended for high-risk VF or VT.
Why the study?
Arrhythmias can be paroxysmal and present across a broad clinical spectrum, making their prevalence difficult to estimate and highlighting the need to review their evaluation and treatment.
This educational review outlines the evaluation and treatment of arrhythmias, emphasizing the importance of an interprofessional team approach.
Answers are grounded in this paper and cite their sources.
Supports team-based arrhythmia care in practice; leaves open prospective trials to refine risk-based recommendations.
A wide range of heart rate issues and irregularities in rhythm are explained by arrhythmia. Brady arrhythmias and tachy arrhythmias, which are depending on the heart rate, are the two main categories of arrhythmia. They are further categorized based on their origin, mode of transmission, and associated symptoms. Patients with an arrhythmia may demonstrate a broad spectrum of clinical presentation from being entirely asymptomatic to sudden cardiac arrest. Because arrhythmias can be paroxysmal, it might be challenging to estimate their actual prevalence. This exercise describes how different arrhythmias are evaluated and treated, and it emphasizes the importance of the interprofessional team in patient management.
No takes yet. Share an insight, caveat, or question.
G. et al. (2026) conducted a review in Patients with arrhythmias including tachyarrhythmias and supraventricular tachycardia syndromes. Beta-blockers was evaluated on Reduction of arrhythmia-related clinical events and symptoms. Beta-blockers are the mainstay of therapy for arrhythmias, with defibrillator recommended for patients with severe risk markers such as ventricular fibrillation or ventricular tachycardia runs.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: